Release Date: April 05, 2021
Expiration Date: April 05, 2022

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

This activity was previously presented as a live webinar with Q&A on March 08, 2021. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Program Overview

Explore new data on MPN presented at the 2020 ASH Annual meeting. In this activity, experts will discuss long-term outcomes of the CONTINUATION-PV trial comparing ropegylated interferon versus hydroxyurea; phase 2 study results of idasanutlin as second-line therapy; the efficacy of PTG-300 for anemia; results from the SIMPLIFY-2 study of momelotinib; data on CPI-0610; outcomes of imetelstat in high-risk patients; navitoclax in relapsed/refractory myelofibrosis; and the potential utility of the LSD1 inhibitor bomedemstat (IMG-7289).

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with myeloproliferative neoplasms.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with myelofibrosis (MF), polycythemia vera (PV), or essential thrombocythemia (ET)
• Outline clinical trials and recent advances in the diagnosis, treatment, and management of MF, PV, or ET
• Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in MPN

Agenda

ASH 2020 Meeting Highlights in Myeloproliferative Neoplasms – Ruben Mesa, MD; Aaron T. Gerds, MD; and John Mascarenhas, MD

Instructions for Participation and Credit

This activity is eligible for credit through April 5, 2022. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Ruben Mesa, MD
Director
Mays Cancer Center
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Dr. Ruben Mesa received his medical degree from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He completed his residency in internal medicine and his fellowship in hematology/medical oncology at Mayo. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in internal medicine and medical oncology. Dr. Mesa is the Director at the Mays Cancer Center, the newly named center at UT Health San Antonio MD Anderson Cancer Center. The Mays Cancer Center is one of only four National Cancer Institute-designated Cancer Centers in Texas. For almost 30 years the cancer center has had a deep focus on providing world-class cancer care, advancing cancer research and educating the next-generation of cancer care scientists and care providers.

Dr. Mesa’s own practice builds on his role as an international expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia. He has been involved in MPN research for more than 20 years. He led the development of National Comprehensive Cancer Network’s panel guidelines, the first U.S. guidelines on the diagnosis and treatment of myelofibrosis, polycythemia vera, and essential thrombocythemia. Dr. Mesa has been the principal investigator or co-principal investigator of more than 70 clinical trials. He was the major research leader contributing to the FDA’s approval of ruxolitinib for polycythemia vera and myelofibrosis. He is currently leading the investigation of several other drugs for these types of cancers.

Aaron T. Gerds, MD
Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Dr. Aaron Gerds received his medical degree from Loyola University of Chicago, Stritch School of Medicine, where he also completed his internal medicine residency/chief residency. He went on to pursue a master of science degree in clinical research methods and epidemiology from Loyola University of Chicago, and a hematology and oncology fellowship at the University of Washington, Fred Hutchinson Cancer Research Center. Dr. Gerds is an Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, and Deputy Director for Clinical Research at the Cleveland Clinic Taussig Institute.

Dr. Gerds is a diplomate in internal medicine, oncology, and hematology from the American Board of Internal Medicine. He holds memberships in the American Society of Clinical Oncology, American Society of Hematology, American Society for Blood and Marrow Transplantation, Society of Hematologic Oncology, SWOG Cancer Research Network, and the MDS Foundation. Dr. Gerds is on the editorial board of the Journal of the National Comprehensive Cancer Network, Cancer Treatment and Research Communications, and the National Cancer Institute Physician Data Query (PDQ), and is a reviewer for many peer-reviewed journals. Dr. Gerds’ clinical and research interests focus on optimizing current treatments, and developing new therapies for patients with myeloproliferative disorders and other myeloid neoplasia.

John Mascarenhas, MD
Associate Professor of Medicine
Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. He is the Director of the Adult Leukemia Program and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs), he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr. Mascarenhas is also the principal investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or study chair of multiple investigator-initiated and industry-sponsored early- and late-phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary leukemia.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-017-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
	NURSING CREDIT MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-017-140

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Ruben Mesa has received honoraria as a consultant from Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Geron, Novartis AG, Samus Therapeutics, Inc., and Sierra Oncology, Inc. He has received grant support related to research activities from AbbVie Inc., Bristol-Myers Squibb, CTI BioPharma Corp., and Incyte Corporation.

Dr. Aaron Gerds has received honoraria related to formal advisory activities from Constellation Pharmaceuticals, CTI BioPharma Corp., Galecto Biotech, PharmaEssentia Corporation, and Promedior, Inc.

Dr. John Mascarenhas has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Constellation Pharmaceuticals, F. Hoffmann-La Roche Ltd, Geron, Incyte Corporation, and PharmaEssentia Corporation. He has received grant support related to research activities from AROG Pharmaceuticals, Inc., CTI BioPharma Corp., F. Hoffmann-La Roche, Forbius, Incyte, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Merus, Novartis AG, and PharmaEssentia.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.

©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.